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Diego Tesauro,b Giancarlo Morellib and Luisa Braccia,cNanoparticles have attracted much attention for their potential application as in vivo carriers of drugs. Labeling of nanopar-
ticles with bioactive markers that are able to direct them toward speciﬁc biological target receptors has led to a new gener-
ation of drug delivery systems. In particular, low molecular weight peptides that remain stable in vivo could be promising
tools to selectively drive nanoparticles loaded with active components to tumor cells.
We reported, recently, that tetrabranched neurotensin peptides (NT4) may be used to selectively target tumor cells with
liposomes. Liposomes functionalized with tetrabranched neurotensin peptide, NT4, and loaded with doxorubicin showed
clear advantages in cell binding, anthracyclin internalization, and cytotoxicity in respect of not functionalized liposomes.
In this study, we compare branched (NT4) versus linear (NT) peptides in the ability to drive liposomes to target cells and deliver
their toxic cargo. We showed here that the more densely decorated liposomes had a better activity proﬁle in terms of drug
delivery. Presentation of peptides to the cell membranes in the grouped shape provided by branched structure facilitates
liposome cell binding and fusion. Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
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Selectivity of therapy is the goal of modern oncology. To achieve
tumor selective therapies, identiﬁcation of tumor ‘markers’, which
should be speciﬁc for cancer cells and/or cancer tissue environ-
ment, is a fundamental prerequisite together with discovery of
selective and effective targeting agents, to be developed as
drugs. Antitumor drugs belong to two main categories: (i) those
that interfere with a cellular pathway typical of the tumor and
(ii) those that bind a tumor-speciﬁc molecule and commit the
activity to their cytotoxic cargo. Traditional chemotherapeutics
such as alkylating agents, antimetabolites, and anthracyclines
belong to the former group together with new generation drugs
as tyrosine kinase inhibitors [1]. This class also includes antibodies
against tumor cell receptors associated to the unregulated
growth and division of the tumor cell, such as ErB2 and EGFR [2].
Antitumor drugs of the latter class, in addition to their targeting
component, which is typically an antibody or a peptide, also carry
a payload like a traditional chemotherapeutic agent [3], or a radio-
isotope [4], or an immune-stimulating factor [5].
Nanoparticles have attracted much attention for their potential
application as in vivo carriers of drugs. The use of liposomes as
drug carrier systems was proposed by Gregoriadis and Ryman
in the early 1970s [6]. These supramolecular aggregates are
nontoxic, biodegradable, and nonimmunogenic. Because of their
size, which typically ranges in mean diameter of 50–300 nm,
liposomes display unique pharmacokinetic properties. These
include clearance via the reticuloendothelial system, which
results in a relatively long systemic circulation time, as well as
hepatic and splenic distribution [7]. Labeling of nanoparticles
with bioactive markers that are able to direct them toward
speciﬁc biological target receptors has led to a new generation
of drug delivery systems [8] belonging to the second class of
antitumor drugs. In facts, peptides and antibodies are theJ. Pept. Sci. 2013; 19: 198–204bioactive markers commonly used to prepare target-selective
supramolecular aggregates, such as micelles and liposomes [9–11].
In particular, lowmolecularweight peptides that remain stable in vivo
could be promising tools to selectively deliver nanoparticles loaded
with active components to tumor cells.
Labeled liposomes loaded with drugs have an advantage
versus drug-conjugated antibodies or peptides in which the
payload they can carry is extremely much larger than that of
single molecule. Besides, labeled liposomes allow bypassing the
harsh conditions needed for conjugating small molecules to
peptides or to antibodies, which may lead to inactivation of the
carrier or of the active molecule or both. We reported, recently,
that tetrabranched neurotensin peptides (NT4) may be used to
selectively target tumor cells with liposomes [12]. Liposomes
functionalized with NT4 and loaded with doxorubicin showed
clear advantages in cell binding, anthracyclin internalization,
and cytotoxicity in respect of not functionalized liposomes.
Peptides lie on the liposome surface and need to be properly
exposed to be able to bind the target. We wanted to analyzeCopyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
NANOPARTICLES EXPOSING NEUROTENSINthe effect of peptide branched structure on target recognition by
liposome functionalized with NT4 peptides. It is well known that
peptides synthesized in a branched form not only become resis-
tant to proteases but also increase peptide biological activity
through multivalent binding [13–17]. In this study, we compare
branched (NT4) versus linear (NT) peptides in the ability to drive
liposomes to target cells and deliver their toxic cargo.Results and Discussion
Peptide Selection and Liposome Formulation
Tetrabranched neurotensin peptides, NT4, can efﬁciently discrimi-
nate between tumor and healthy tissues in human surgical
samples from colon and pancreas adenocarcinoma in a high
number of patients, with good statistical signiﬁcance, whereas
monomeric neurotensin peptides, NT, cannot [18,19]. Accordingly,
tumor cell binding was extremely much lower for the monomeric
NT compared with NT4. Moreover, liposomes ﬁlled with doxorubi-
cin (Doxo) resulted much more efﬁcient in intracellular drug
delivery when decorated with tetrabranched NT short functional
8–13 fragment compared with analogous undecorated particles.
We want now to verify if facilitated target recognition occurs
even when using monomeric peptides or it happens only when
neurotensin peptides are in a grouped shape on the external
liposome surface. For this purpose, 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC) liposomes decorated with different
amounts of neurotensin monomeric peptides have been
prepared by following the procedure already described [12].
The monomeric linear peptides corresponding to the neuroten-
sin entire sequence (NT1–13) and corresponding to the shortFigure 1. Schematic representation of the neurotensin functionalized pepti
tensin derivative (NT8–13)4-L-(C18)2 used in the previous study [12].
J. Pept. Sci. 2013; 19: 198–204 Copyright © 2013 European Peptide Society aactive sequence (NT8–13) were functionalized at the C-terminus
with two ethoxilic linkers (L) and with an hydrophobic moiety,
(C18)2, containing two 18-carbon alkyl chains atoms, in order
to insert them in DOPC liposomes. The chemical structures
of the neurotensin functionalized peptides (NT1–13)L-(C18)2 and
(NT8–13)L-(C18)2 are reported in Figure 1 along with the
tetrabranched neurotensin derivative (NT8–13)4-L-(C18)2 used in
the previous study. Peptide derivatives have been synthesized by
solid phase methods using a Rink amide resin [20]. An orthogonal
protected lysine residue was bound to the solid support, and then,
two Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid
(Fmoc-Ahoh-OH) spacers and the hydrophobic moiety N,N-
dioctadecylsuccinamic acid were sequentially bound to lysine side
chain, whereas the amino acidic sequences of NT8–13 or NT1–13
were added on the lysine N-a function. Both peptide derivatives
(NT1–13)L-(C18)2 and (NT8–13)L-(C18)2 were puriﬁed by HPLC on C4
column and obtained in good yield and high purity.
Pure DOPC liposomes and mixed DOPC/(NT1–13)L-(C18)2
and DOPC/(NT8–13)L-(C18)2 liposomes at several molar ratios
(95:5, 90:10, and 85:15) of the two amphiphilic components
were prepared as already reported for DOPC liposomes contain-
ing the tetrabranched neurotensin derivative (NT8–13)4-L-(C18)2,
prepared at 95:5 ratio. The ratio of DOPC and amphiphilic
neurotensin derivatives has been modulated to verify if the
amount of the exposed peptide could inﬂuence cell binding
and cytotoxicity of the entire liposomes ﬁlled with doxorubicin.
In the case of the already studied DOPC/(NT8–13)4-L-(C18)2 95:5
liposomes, four copies of NT8–13 peptide are present for each
monomer thus corresponding to 80:20 in DOPC/peptide ratio.
Preparation of liposomes containing 20% weight of monomeric
neurotensin derivatives (80:20 ratio) is not feasible usingdes (NT8–13)L-(C18)2 and (NT1–13)L-(C18)2 and of the tetrabranched neuro-
nd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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0monomeric derivatives. Therefore, the total amount of exposed
peptides remains, for all the three obtained compositions, lower
than in the case of liposomes with tetrabranched derivative.
The size of pure DOPC and mixed DOPC/NT-peptide liposomes
at several molar ratios (R = 0, R = 95/5, R = 90/10, and R = 85/15)DOPC
DOPC/(nT8-13)L-(C18)2 95/5
DOPC/(nT8-13)L-(C18)2 90/10
DOPC/(nT8-13)L-(C18)2 85/15
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Figure 2. DLS spectra of DOPC/(NT8–13)L-(C18)2 systems at different
molar ratios (R = 0, 95:5, 90:10, 85:15).was assessed by dynamic light scattering (DLS). Measurements
were performed at θ= 173 on liposomes at 5  104M concentra-
tion in 0.1M phosphate buffer at pH 7.4. Hydrodynamic radius
(RH) distribution function of DOPC/(NT8–13)L-(C18)2 liposomes
are reported in Figure 2, and RH values and polydispersity index
of all systems are summarized in Table 1. All aggregates with theTable 1. Composition of the lipid bilayer and structural parameters (hyd
liposomes
Formulation Composition of
the lipid bilayer
DOPC/Doxo
DOPC/(NT1–13)L-(C18)2/Doxo 95/5
DOPC/(NT1–13)L-(C18)2/Doxo 90/10
DOPC/(NT1–13)L-(C18)2/Doxo 85/15
DOPC/(NT8–13)L-(C18)2/Doxo 95/5
DOPC/(NT8–13)L-(C18)2/Doxo 90/10
DOPC/(NT8–13)L-(C18)2/Doxo 85/15
wileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Peexception of the sample with R = 85/15 showed a distribution
clearly mono-modal, i.e. there is a presence of a single mode with
a radius of ~ 60 nm (Table 1). These results indicate that the size
of DOPC liposomes does not change when low amounts of
NT8–13 or NT1–13-peptide monomers (≤10%) are added to the
formulation. Instead, liposomes containing high percentage of
NT8–13 or NT1–13-peptide monomers (R = 85/15) present a
bimodal distribution with a slow and a fast mode, whose mean
radius are 71 21 nm and 28 5 nm, respectively.
Doxorubicin, which has a dual function being a cytotoxic
antibiotic and a ﬂuorescent probe, was loaded into liposomes
by using the pH gradient method. The liposomal formulations
designated as DOPC/Doxo, DOPC/(NT1–13)L-(C18)2/Doxo and
DOPC/(NT8–13)L-(C18)2/Doxo were obtained and characterized
measuring the Doxo loading content (DLC, deﬁned as the weight
ratio of encapsulated Doxo versus the amphiphilic moieties). The
DLC values obtained for mixed liposomes (R = 95/5 and R= 90/10)
are comparable with the value found for pure DOPC liposomes,
whereas the DLC for liposomes containing 15% of peptide
monomer decrease of about 30%. This result clearly indicates
that at this molar ratio, several changes occur in liposomal
structure (see DLS results), and as a consequence, the amount
of encapsulated drug decrease. Because of the low DLC value
and to the simultaneous presence of supramolecular structures
with different size and shape, mixed DOPC liposomes containing
15% of peptide monomer were kept away from in vitro cellular
investigations.Cell Binding and Internalization
Liposomes carrying NT1–13 (DOPC/(NT1–13)L-(C18)2/Doxo) or NT8–13
(DOPC/(NT8–13)L-(C18)2/Doxo), at 95:5 and 90:10 molar ratio
between the two amphiphilic components, were compared with
the analogous liposomes decorated with NT4, DOPC/(NT8–13)4-
L-(C18)2/Doxo, by confocal microscopy experiments. HT29 and
TE671 cells were incubated for 30min at 25 C with liposome
formulations 1mM (in the case of liposomes decorated with
branched NT) or 5mM (for liposomes decorated with monomeric
NT or for not decorated liposomes) calculated as molarity of Doxo.
Figure 3 shows confocal microscopy images and 3D cell surface
plot of HT29 and TE671 cells incubated with liposomes decorated
either with monomeric NT8–13 or with tetrabranched NT8–13 or
with nude liposomes. Internalized Doxo is much higher when the
carrier is a tetrabranched peptide compared with a monomeric
peptide. The amount of Doxo brought in by the monomeric-
decorated liposomes increases with the increase of peptiderodynamic radii, RH, and polydispersity index, PI) data of the obtained
RH (nm) SD PI SD
61 20 0.079 0.02
60 23 0.098 0.03
58 21 0.101 0.03
89 27 23 4 0.244 0.05
59 27 0.122 0.03
57 24 0.110 0.03
71 21 28 5 0.194 0.05
ptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 198–204
Figure 3. Liposomes binding on HT29 and TE671 cell lines. HT29 and TE671
incubated with DOPC/(NT8–13)4-L-(C18)2/Doxo, DOPC/Doxo (panel A) or
with DOPC/(NT8–13)L-(C18)2/Doxo 90:10, DOPC/(NT8–13)L-(C18)2/Doxo 95:5
(panel B) analyzed with confocal microscopy. Cell membrane is stained
with Lectin-Atto 647.
NANOPARTICLES EXPOSING NEUROTENSINon the liposome surface being equal to that of nondecorated
particles of 95/5 molar ratio (Figure 3)2
0
1Cytotoxicity
HT29 and TE671 cells were incubated with various concentra-
tions, from 8 nM to 25mM, of DOPC/(NT1–13)L-(C18)2/Doxo 90:10,
DOPC/(NT8–13)L-(C18)2/Doxo 90:10, or DOPC/(NT8–13)4-L-(C18)2/
Doxo. After 8 h of incubation, cells were washed and incubated
for 3 days. Washing was performed to avoid diffusion of freeJ. Pept. Sci. 2013; 19: 198–204 Copyright © 2013 European Peptide Society aDoxo from the liposomes during the 3-day incubation period.
As reported in Figure 4, DOPC/(NT1–13)L-(C18)2/Doxo and DOPC/
(NT8–13)L-(C18)2/Doxo exert a very mild cytotoxic effect when
compared with the branched-decorated DOPC/(NT8–13)4-L-(C18)
2/Doxo liposomes (Figure 4) [11]. In facts, in HT29 in vitro model,
there is more than one log of difference between DOPC/(NT8–13)
4-L-(C18)2/Doxo andDOPC/(NT1–13)L-(C18)2/Doxo or DOPC/(NT8–13)
L-(C18)2/Doxo. In TE671, again, DOPC/(NT8–13)4-L-(C18)2/Doxo is
at least eight times better than DOPC/(NT1–13)L-(C18)2/Doxo or
DOPC/(NT8–13)L-(C18)2/Doxo.
1,2-Dioleoyl-sn-glycero-3-phosphocholine mixed liposomes
containing 5% of peptide monomer, DOPC/(NT1–13)L-(C18)2/Doxo
95:5 and DOPC/(NT8–13)L-(C18)2/Doxo 95:5, were also examined;
results indicate that in this experimental conditions, where
long-time incubation may have a leveling effect, no differences
were detectable when compared with the 90:10 analogs
reported previously.
Flow Cytometry
HT29 and TE671 cells were incubated with 5 mM liposomes
decorated with monomeric NT or with 1mM liposomes
decorated with branched NT (data not shown). Again,
liposomes decorated with monomeric peptides showed much
lower efﬁciency in Doxo delivery to cancer cells compared with
those containing branched peptides. To verify whether the
ability of liposomes to fuse with the cells and deliver Doxo
was related to the surface concentration of peptides, we
compared liposomes prepared with different DOPC/peptide
monomer ratio. The more densely decorated liposomes
DOPC/(NT8–13)L-(C18)2/Doxo 90:10 (shown in Figure 5) had a
better activity proﬁle than those exposing a lower concentra-
tion of peptide (DOPC/(NT8–13)L-(C18)2/Doxo 95:5) (Figure 5).
Identical result was given by DOPC/(NT1–13)L-(C18)2/Doxo at
two different molar ratios (not shown). The best activity
response was again given by branched-decorated liposomes,
which indeed are those with the highest concentration of
peptide on the particle surface.
Material and Methods
Protected Na-Fmoc-amino acid derivatives, coupling reagents,
and Rink amide MBHA (methylbenzhydrylamine) resin were pur-
chased from Calbiochem-Novabiochem (Läufelfingen, Switzerland).
The Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid
(Fmoc-Ahoh-OH) was purchased from Neosystem (Strasbourg,
France). The N,N-dioctadecylsuccinamic acid was synthesized
according to published methods [21]. (8S,10S)-10-(4-amino-5-hy-
droxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-
hydroxyacetyl)-1-methoxy-7,8,9,10- tetra hydro-tetracene-5,12-dione;
doxorubicin HCl was purchased from Sigma-Aldrich. DOPC
was purchased from Avanti Polar Lipids (Alabaster, AL, USA).
All other chemicals were commercially available by Sigma-
Aldrich (Bucks, Switzerland) or LabScan (Stillorgan, Dublin,
Ireland) and were used as received unless otherwise stated.
All solutions were prepared by weight with doubly distilled
water. Solid phase peptide synthesis was performed on a
433A Applied Biosystems automatic synthesizer (Carlsbad,
California). Analytical LC-MS analyses were performed by using
Finnigan Surveyor MSQ single quadrupole electrospray ioniza-
tion (Finnigan/Thermo Electron Corporation San Jose, CA),
column: C4-Phenomenex eluted with H2O/0.1% TFA (A) andnd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Figure 4. Cytotoxicity HT29 and TE671 cells were incubated with different concentration of liposomes decorated either with tetrabranched NT (left) or
with monomeric NT (right) or with nude liposomes (DOPC-doxo). After 8 h of incubation, cells were washed and grown for 3 days.
Figure 5. Flow cytometry analysis. HT29 and TE671 cells were incubated with DOPC/(NT8–13)L-(C18)2/Doxo 90:10 (black dark gray), DOPC/(NT8–13)
L-(C18)2/Doxo 95:5 (light gray) and with DOPC/Doxo liposomes (dotted line). Fluorescent signals were measured with BD FACSCalibur.
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2CH3CN/0.1% TFA (B) from 20–80% over 20min at a ﬂow rate of
0.8ml/min. The crude peptides were puriﬁed by RP-HPLC on
an LC8 Shimadzu HPLC system (Shimadzu Corporation, Kyoto,
Japan) equipped with a UV lambda-Max Model 481 detector using
a Phenomenex (Torrance, CA) C4 (300Å, 250 21.20mm, 5m)
column eluted with H2O/0.1% TFA (A) and CH3CN/0.1% TFA
(B) from 20–80% over 20min at a ﬂow rate of 20mlmin1.
UV measurements were performed on a UV–vis Jasco V-5505
spectrophotometer (Easton, MD) equipped with a Jasco ETC.-
505T Peltier temperature controller with a 1-cm quartz cuvettewileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Pe(Hellma). The liposomes were extruded using a mini-extruder
purchased from Avanti Polar Lipids.
Peptide Conjugate Synthesis
Peptide synthesis was carried out in solid phase under standard
conditions using Fmoc strategy on Rink amide MBHA resin
(0.65mmol g1, 0.10mmol scale, and 0.154 g) [20]. After the
Fmoc removal from the resin, the coupling of the Dde-Lys
(Fmoc)-OH residue was performed by using HOBt/PyBop/DIPEAptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 198–204
NANOPARTICLES EXPOSING NEUROTENSIN(1/1/2) according to the standard protocols of solid phase
peptide synthesis (single coupling with four equivalents of amino
acid in DMF for a reaction time of 1 h). Successively, side chain
of lysine residue was deprotected with DMF/piperidine mixture
(70/30), and the two Fmoc-Ahoh-OH hexaoxoethylene linker
and the N,N-dioctadecylsuccinamic acid were sequentially
condensed as previously reported [20]. The lipophilic derivative
was coupled after dissolution in DMF/CH2Cl2 (50:50). Then, Dde
protecting group of the N-terminus of the lysine was removed
with DMF/Hydrazine (98/2), and the peptide chain of NT8–13 or
NT1–13 was elongated by sequential coupling by the standard
HOBt/PyBop/DIEA procedure with DMF as solvent and Fmoc
deprotection of the Fmoc-amino acid derivatives. Peptides were
fully deprotected and cleaved from the resin with TFA with
2.5% (v/v) water, 2.5% (v/v) TIS as scavengers, at room tempera-
ture, and then precipitated with ice-cold water, ﬁltered, dissolved
in water, and lyophilized. The crude peptide derivatives were
puriﬁed by RP-HPLC. Purity and identity were assessed by analyt-
ical LC-MS analyses. The ﬁnal yields of puriﬁed peptides ranged
between 20% and 40%.NT113ð ÞL C18ð Þ2 Rt ¼ 16:76 min;MS ESIð Þ : Mþ 2Hþ½ =2 ¼ 1546:7 amu; Mþ 3Hþ½ =3
¼ 1031:6 amu; Mþ 4Hþ½ =4 ¼ 773:9 amu MW : 3091:4ð Þ:
NT813ð ÞL C18ð Þ2 Rt ¼ 12:05 min;MS ESIð Þ : Mþ 2Hþ½ =2 ¼ 1105:5 amu; MW : 2210:2ð Þ:2
0
3Liposome Preparation and DLS Characterization
All solutions were prepared by weight and buffered at pH7.4 using
0.1M phosphate buffer. The pH was controlled using pH meter
MeterLab PHM220. Mixed aggregates of DOPC/(NT1–13)L-(C18)2
and DOPC/(NT8–13)L-(C18)2 at several molar ratio (95:5, 90:10, and
85:15) were prepared as reported [12]: the two amphiphiles were
dissolved in a small amount of MeOH/CHCl3 (50:50); subsequently,
a thin ﬁlm of amphiphiles was obtained by evaporating the solvent
by slowly rotating the tube containing the solution under a stream
of nitrogen. Lipid ﬁlm wasc hydrated by addition of 0.1M
phosphate buffer (pH7.4), sonicated for 30min and extruded 21
times through a polycarbonate membrane (100nm pore size).
The same procedure was used also to prepare pure DOPC lipo-
somes. The effective amount of NT1–13 or NT8–13 peptide enclosed
in the several liposomal formulations was conﬁrmed by UV–vis at
270 nm (Tyr residue absorbance). After dilution of samples at
2.0  104M concentration and centrifuged at room temperature
at 13000 rpm for 5min, hydrodynamic radii (RH) were measured
by DLS. The setup for the DLS measurement was a Zetasizer Nano
ZS (Malvern Instruments, Westborough, MA) that employs a 173
backscatter detector. Other instrumental settings are measurement
position (mm): 4.65; attenuator: 8; temperature 25 C; cell: dispos-
able sizing cuvette.
Doxorubicin Loading
1,2-Dioleoyl-sn-glycero-3-phosphocholine/Doxo, DOPC/(NT1–13)
L-(C18)2/Doxo and DOPC/(NT8–13)L-(C18)2/Doxo liposomal
formulations were prepared by loading doxorubicin HCl
into liposomes by using the pH gradient method. Brieﬂy, the
liposomal solution was prepared as reported previously at
pH 4.0 using 0.1M citrate–phosphate buffer. The pH wasJ. Pept. Sci. 2013; 19: 198–204 Copyright © 2013 European Peptide Society aadjusted from 4.0 to 7.4 by dropwise addition of a 1.0M stock so-
lution of NaOH. Next, Doxo was added to liposomal solution from
aqueous stock solution in order to have a drug/lipid ratio of 0.1.
The suspension was stirred for 30min at room temperature. The
Doxo concentration in all experiments was determined by
spectroscopic measurements (UV or ﬂuorescence) using calibra-
tion curves obtained by measuring absorbance at 480 nm.
Subsequently, unloaded Doxo was removed by gel ﬁltration with
a Sephadex G50 column pre-equilibrated with 2.5mM phosphate
buffer at pH 7.4. The drug loading content (DLC, deﬁned as
the weight ratio of encapsulated Doxo versus the amphiphilic
moieties) was quantiﬁed by subtraction of the amount of Doxo
removed from the total amount of Doxo loaded.
Cell Cultures
HT29 human colon adenocarcinoma and TE671 human
rhabdomyosarcoma cells were grown in their recommended
medium, respectively, McCoy’s 5A or DMEM supplemented
with 10% fetal calf serum, 200 mg/ml glutamine, 100 mg/mlstreptomycin, 60mg/ml penicillin, and maintained at 37 C,
5% CO2. Cell lines were purchased from Istituto Zooproﬁlattico
Sperimentale (Brescia, Italy).Cell Binding and Internalization
HT29 and TE671 were plated at the density of 25 000 cells/well
and, after overnight adhesion, incubated for 30min at 25 C
with liposomes diluted in completed medium. Liposomes
concentration, calculated as molarity of Doxo, was 1 mM for
liposomes decorated with branched NT, 5 mM for liposomes
decorated with monomeric NT or for not decorated liposomes.
Cells were ﬁxed for 10min in 4% PFA-TBS (Tris 50mM NaCl
150mM pH 7.4), and then, the cellular membrane was stained
with lectin-Atto 647 0.5 mg/ml in 0.3% BSA–TBS for 15min at
25 C. Each step was followed by three washes with TBS.
Images were taken with a TCS SP5 Leica confocal microscope
(514lex 550–600 lem for doxo; 633 lex 660–690 lem for Atto
647). All images were then analyzed with ImageJ software.
Experiments were repeated three times, at least.Cytotoxicity
HT29 and TE671 were plated at a density of 5000 cells/well in
96-well microplates and grown for 24 h and then were exposed
to different concentration of liposomes (8 nM–25 mM). After
8 h of incubation, cells were washed and grown for 3 days at
37 C with complete medium. 3-(4,5-Dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT), 50 mg/ml was then added
for 3.5 h at 37 C. Cells are then lysed with DMSO, and the
absorbance of MTT salts of living cells was read at a spectropho-
tometer. Results were analyzed by nonlinear regressionnd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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4analysis using GraphPaD Prism 5.03 software. Experiments were
repeated three times, at least.
Flow Cytometry Analysis
The various liposomes preparations with different ratio of
DOPC/peptide monomer were incubated with HT29 and TE671
cells and analyzed by ﬂow cytometry. Brieﬂy, 100 000 cells/well
were incubated in 96well U-bottom plates for 30min at 25 C
with 5 mM of DOPC/(NT8–13)4 L-(C18)2/Doxo, DOPC/(NT8–13)
L-(C18)2/Doxo, and DOPC/(NT1–13)L-(C18)2/Doxo at the molar
ratios of 95:5, 90:10, and DOPC/Doxo, diluted in completed
medium and then ﬁxed for 10min with 4% PFA-TBS. Flow
cytometry measurements were obtained analyzing 20 000
events with a BD FACSCalibur (BD, NJ. USA). Experiments were
repeated three times, at least.Conclusions
Labeled nanoparticles are of growing interest in the ﬁeld of drug
delivery system. These are very smart new drugs that can be di-
rected against selective targets. In this study, we demonstrated that
it is not only important to choose the right bioactive marker that
brings the molecule to its target but also the mode of exposure of
the carrier on the particle surface, and its amount, may be crucial.
We showed here that the more densely decorated liposomes
had a better activity proﬁle in terms of drug delivery. Unfortu-
nately, preparation of liposomes containing 15% or 20% weight
of monomeric neurotensin derivatives could not be obtained by
using monomeric peptide derivatives. We compared growing
concentrations of linear peptides and observed that the increase
in peptide exposure correlated with an increased activity. None-
theless, a high concentration of liposome-inserted peptides
resulted in a drop of liposome stability.
On the other hand, the use of branched peptides in the
amphiphilic monomer yields a higher concentration of peptide,
i.e. a lower DOPC/peptide ratio. As a result, liposome decorated
with branched peptides has a better proﬁle in drug delivery, with
respect to liposomes decorated with correspondent monomeric
peptides. This achievement might be seen as a general approach
to increase the exposure of carriers on the surface of the
nanoparticles, which is a frequently wanted matter. The use of
multimeric peptides as decorating units of nanoparticle has,
eventually, the merit of increasing the amount of hydrophilic
carrier to be exposed to the target cell. Besides, the presentation
of peptides in a grouped shape facilitates binding and fusion of
particles to cells.
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